Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS

Pomerantz LLP has filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) and certain officers for alleged securities fraud. The lawsuit claims Defendants made materially false and misleading statements about the efficacy of Revita, their metabolic therapy device, while conducting public offerings in August-September 2025. On January 29, 2026, Fractyl disclosed disappointing six-month data from the REMAIN-1 Midpoint Cohort showing only 4.5% weight regain versus 7.5% in the sham arm, significantly below expectations. The disclosure revealed operational issues at one clinical site compromised study integrity. Following the announcement, Fractyl's stock price plummeted 68.03% on January 29, 2026, and fell an additional 21.37% on January 30, 2026.